Commentary: Chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines

Journal of Oncology Practice

Volumn 7, Issue 1, 2011, Pages 17-18

  Lyman, By Gary H ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; DOSE CALCULATION; DRUG TOXICITY; EVIDENCE BASED PRACTICE; HEMATOLOGIC DISEASE; HUMAN; NEOPLASM; NEUTROPENIA; NOTE; OBESITY; PRACTICE GUIDELINE;

EID: 79955697958     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2010.000200     Document Type: Note

References (16)

1. Lyman GH: Chemotherapy dose intensity and quality cancer care. Oncology (Williston Park) 14:16-25, 2006 (suppl 9)
2. Bonneterre J, RochéH, Kerbrat P, et al: Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23:2686-2693, 2005 (Pubitemid 46179458)
3. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205-1211, 1998 (Pubitemid 28407086)
4. Lepage E, Gisselbrecht C, Haioun C, et al: Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 4:651-656, 1993 (Pubitemid 23291810)
5. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 21:4524-4531, 2003 (Pubitemid 46594022)
6. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. J Clin Oncol 22:4302-4311, 2004 (Pubitemid 41185151)
7. Rosner GL, Hargis JB, Hollis DR, et al: Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: Results from Cancer and Leukemia Group B study 8541. J Clin Oncol 14:3000-3008, 1996 (Pubitemid 26371459)
8. Griggs JJ, Culakova E, Sorbero ME, et al: Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol 25:277-284, 2007 (Pubitemid 350010638)
9. Griggs JJ, Sorbero ME, Lyman GH: Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165:1267-1273, 2005 (Pubitemid 40989591)
10. Sparreboom A, Wolff AC, Mathijssen RH, et al: Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707-4713, 2007 (Pubitemid 350086471)
11. Lyman GH: Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 7:99-108, 2009
12. Mayers C, Panzarella T, Tannock IF: Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91:2246-2257, 2001 (Pubitemid 32552809)
13. Lopes,-Serrao MD, Gressert Ussery SM, Hall RG II, et al: Evaluation of chemotherapy- induced severe myelosuppression incidence in obese patients with capped dosing. J Clin Oncol 7:13-17, 2011
14. Field KM, Kosmider S, Jefford M, et al: Chemotherapy dosing strategies in the obese, elderly and thin patients: Results of a nationwide survey. J Oncol Pract 4:108-113, 2008 (Pubitemid 351952696)
15. Shayne M, Culakova E, Wolff D, et al: Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer 115: 5319-5328, 2009
16. Griggs JJ, Culakova E, Sorbero ME, et al: Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25: 2522-2527, 2007 (Pubitemid 47041224)